Head & Neck/Thyroid Cancers
Conference Coverage
Pembro/chemo combo fails to improve event-free survival in head and neck cancer
Some trends favored chemoradiation plus pembrolizumab over chemoradiation alone, but KEYNOTE-412 failed to meet primary endpoint.
Conference Coverage
First drug for desmoid tumors: ‘Impressive’ data for nirogacestat
Nirogacestat has shown a significant improvement in progression-free survival and also a reduction in symptoms and better quality of life.
Clinical Topics & News
Trends in Palliative Care Utilization and Facility Type for Stage IV Esophageal Cancer: A National Cancer Database Analysis
Clinical Topics & News
Demographics in Early vs Late-Stage Laryngeal Squamous Cell Carcinoma: A NCDB Review
News
Nearly 30% of U.S. cancer deaths linked to smoking
Getting more people to screen for lung cancer in the United States is also important, given that only 6.6% of eligible people in 2019 received...
News
At-home test for oral/throat cancer launched in U.S.
It is not covered by medical insurance, and is not approved by the Food and Drug Administration.
News
Oncologists often misinterpret posttreatment HNSCC scan details
Study contends that discrepancies could threaten patient outcomes by obscuring true level of response.
News
Thyroid autoimmunity linked to cancer, but screening not advised
While disorders such as Graves’ disease may double the odds of tumors, the overall risk remains low.
News
The ‘great dynamism’ of radiation oncology
Highlights from this research reveal how high-tech radiotherapy, such as hypofractionation and stereotactic body radiotherapy, has improved care...
News
Taste dysfunction in head and neck cancer due to radiation dose
Researchers identified doses to the oral cavity that predicted 15%, 25%, and 50% probability of taste dysfunction.
